OptiNose (OPTN) H.C. Wainwright 26th Annual Global Investment Conference summary

Conference overview

• H.C. Wainwright hosted its 26th Annual Global Investment Conference from September 9th-11th, 2024, featuring presentations, panels, and one-on-one meetings across multiple sectors.

• The event included a session with the CEO of a therapeutics company specializing in ear, nose, and throat disorders.

Product and market update

• XHANCE became the first FDA-approved product for chronic sinusitis in 2024, expanding its label beyond nasal polyps.

• The new indication increases the addressable patient population by up to 10x, with a total market potential of 30 million patients and a $30 billion TAM.

• 2023 net revenue was $71 million, with peak net revenue potential estimated at $300 million in the specialty segment.

• The company is launching with its existing 75-territory specialty sales force and a modest increase in launch investment.

Clinical and competitive landscape

• Chronic sinusitis is a common, chronic inflammatory disease, often mismanaged with antibiotics and standard nasal steroids lacking proven efficacy.

• XHANCE uses a patented exhalation delivery system, enabling deeper drug deposition in target sinus areas.

• Clinical trials showed significant symptom improvement and up to 66% reduction in acute exacerbations.

• Over 80% of patients are dissatisfied with current therapies, and 87% of providers are likely to prescribe XHANCE when exposed to its profile.